Form D · Pharmaceuticals
Athos Therapeutics, Inc.
Torrance, CA · CIK 0001885079
Offering snapshot reported May 15, 2026 · SEC filing
- Reported sold
- $10.3M Offering amount: $20M
- Investors reported
- 40 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2026 | Initial | $10,282,887 | No comparison | 40 | SEC filing |
| Feb 6, 2024 | Initial | $7,556,334 | No comparison | 30 | SEC filing |
| Nov 17, 2021 | Amendment | $20,416,499 | $7,236,660vs Sep 28, 2021 | 103 | SEC filing |
| Sep 28, 2021 | Initial | $13,179,839 | No comparison | 58 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-584143
Source: Form D, filed May 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joel Cohen | Director |
| Dimitrios Iliopoulos | Director, Executive |
| Carl Mc Kinzie | Director |
| Allan J. Pantuck | Director, Executive |
| Laurence Stein | Director |
| Anthony Zingale | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1123 W. Carson St.
Torrance, CA, 90502
Torrance, CA, 90502